Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY59-8862 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BAY59-8862 (Cytotoxic Taxane) | DRUG | 1 h intravenous infusion every 3 weeks |
Inclusion Criteria: * Female patients with a proven diagnosis of metastatic breast cancer * Measurable disease as defined by the presence of at least one measurable lesion * Patients must have received at least 3 weeks of continuous therapy with Taxane * patient must subsequently develop progressiv...
BAY59-8862 is an investigational small molecule being studied for the treatment of breast cancer, non-small-cell lung cancer, and renal cell carcinoma. It has been evaluated in Phase 2 clinical trials for these oncology indications, including taxane-resistant metastatic breast cancer and taxane-resistant non-small-cell lung cancer.
BAY59-8862 is being developed by Bayer AG, a German pharmaceutical company. Bayer AG trades on the OTC market under the ticker symbol BAYRY. The drug is an investigational small molecule in the oncology therapeutic area.
BAY59-8862 is in Phase 2 clinical development. It has completed three Phase 2 trials, one each in breast cancer, non-small-cell lung cancer, and renal cell carcinoma. The drug is investigational and has not been approved by regulatory authorities.
BAY59-8862 has completed three Phase 2 trials: NCT00044525 in taxane-resistant metastatic breast cancer with 82 patients, NCT00044538 in taxane-resistant non-small-cell lung cancer with 102 patients, and NCT00044564 in advanced renal cell carcinoma with 54 patients. All trials are completed.
BAY59-8862 is not FDA approved. It is an investigational drug that has completed Phase 2 clinical trials for breast cancer, non-small-cell lung cancer, and renal cell carcinoma. The drug remains in clinical development and has not received marketing approval.